Core Points - Dogwood Therapeutics, Inc. has entered into a securities purchase agreement to sell 578,950 shares of common stock at $8.26 per share, expecting gross proceeds of approximately $4.8 million [1][2] - The net proceeds will be used to advance the clinical development of its lead candidate, Halneuron®, and for working capital and general corporate purposes [1] - The offering is expected to close on March 14, 2025, subject to customary closing conditions [1] Company Overview - Dogwood Therapeutics is a development-stage biopharmaceutical company focused on non-opioid treatments for chronic and acute pain [5] - The company’s lead candidate, Halneuron, is a voltage-gated sodium channel modulator aimed at reducing pain transmission, with interim data from its Phase 2b trial expected in Q4 2025 [5] - Dogwood also has an antiviral program that includes IMC-1 and IMC-2, targeting conditions related to herpesvirus reactivation, with IMC-1 progressing to Phase 3 for fibromyalgia and IMC-2 advancing to Phase 2b for Long-COVID [6]
Dogwood Therapeutics, Inc. Announces Pricing of $4.8 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules